Methylphenidate and Short-Term Cardiovascular Risk
Miguel Garcia-Argibay1,2, Paul-Christian Bürkner3, Paul Lichtenstein2
1School of Medical Sciences, Örebro University, Faculty of Medicine and Health, Örebro, Sweden.
JAMA Network Open
|March 6, 2024
Summary
Short-term methylphenidate use for attention-deficit/hyperactivity disorder (ADHD) showed a small increased cardiovascular risk in individuals. Careful risk-benefit assessment is advised before initiating methylphenidate treatment, irrespective of prior cardiovascular history.
Area of Science:
- Cardiology
- Psychiatry
- Pharmacology
Background:
- Concerns exist regarding cardiovascular safety of ADHD medications.
- Evidence on cardiovascular risk associated with methylphenidate is mixed.
Purpose of the Study:
- To evaluate the association between short-term methylphenidate use and cardiovascular events.
- To compare cardiovascular risk in methylphenidate users versus non-users with ADHD.
Main Methods:
- Retrospective, population-based cohort study using Swedish national registry data.
- Matched 26,710 methylphenidate users with 225,672 non-users (aged 12-60 years).
- Bayesian within-individual design to compare cardiovascular event rates before and after treatment initiation.
Main Results:
- Methylphenidate users had a higher incidence of cardiovascular events (IRR, 1.41) compared to controls (IRR, 1.18).
- There was an 87% posterior probability of increased cardiovascular events post-treatment initiation in users.
- No significant difference in risk increase was observed between individuals with and without prior cardiovascular disease.
Conclusions:
- Short-term methylphenidate use is associated with a small increase in cardiovascular risk.
- The study suggests careful consideration of the risk-benefit profile before prescribing methylphenidate.
- Cardiovascular history did not appear to significantly alter the risk increase associated with methylphenidate.
Related Concept Videos
01:28Adrenergic Agonists: Mixed-Action Agents
709
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
709
01:29Stimulants
195
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
195
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
801
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
801
01:24Antiasthma Drugs: Methylxanthines
228
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
228
01:30Attention-Deficit/Hyperactivity Disorder
67
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
67
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K